Niche products, US sales boost Wockhardt: Finquest
Anand Bagaria, senior research analyst, Finquest explains to CNBC-TV18 that pharma major Wockhardt has posted a strong run in terms of a stock performance as well as fundamentals and gained over 250% from the start of the year.